A Practical Framework for Smooth Tech Transfer
Introduction
Technology transfer is a critical step in the development of gene therapy. It is the point where process knowledge, analytical methods, documentation, and operational expectations must come together to support reliable execution at the next stage of manufacturing.
A successful technology transfer is not simply the movement of documents from one team or facility to another. It is a structured process of translating development knowledge into manufacturing execution. That includes assessing process fit, confirming analytical readiness, aligning responsibilities, and establishing the right level of control before engineering or GMP activities begin.
At its best, tech transfer creates a stronger foundation for scale-up by bringing together process development, analytical development, quality, manufacturing, supply chain, and program governance around a shared plan. The goal is not to remove complexity; it is to manage complexity responsibly, with decisions grounded in evidence, quality, and accountability.
What Tech Transfer Means in Gene Therapy Manufacturing
In gene therapy manufacturing, technology transfer is the structured transfer of process knowledge, analytical methods, materials information, documentation, and execution requirements. In practice, this often includes both process transfer and analytical method transfer. This approach aligns with the World Health Organization’s guidelines on transfer of technology in pharmaceutical manufacturing, which describe technology transfer as a planned and controlled process for moving product and process knowledge between development and manufacturing environments.
Process transfer focuses on how the product is made, including unit operations, raw material considerations, process parameters, scale-up strategy, and equipment compatibility. Analytical method transfer focuses on how the process and product are evaluated, including the assays, controls, and documentation required to establish methods in the receiving environment.
In gene therapy, this work is rarely straightforward. Programs often involve product-specific behavior, scale-dependent effects, and assays that continue to mature as development progresses. Regulatory expectations also become more demanding as programs advance. For those reasons, a strong CDMO tech transfer depends on more than technical capability alone: it requires coordination, transparency, and a shared commitment to doing the work the right way.
Why Tech Transfer Is a Defining Moment for Scale-Up
Scale-up is not only an operational milestone. It is a test of how well process knowledge can support reliable execution under new conditions.
A process that performs well in one setting may require further confirmation when transferred to a different team, facility, equipment train, or quality system. Even when core process elements remain the same, the context around them changes. Suite layout, operator practices, assay execution, and documentation workflows can all influence performance.
A well-planned tech transfer provides a structured approach to understanding this complexity, prioritizing risk, and supporting informed decisions before GMP execution begins. For programs advancing toward clinical manufacturing or commercial readiness, that structure supports better alignment across teams and a more reliable operational foundation.
The 5 Core Phases of a CDMO Tech Transfer Framework
The framework below reflects established technology transfer principles, including the importance of cross-functional planning, knowledge transfer, risk assessment, readiness activities, and documented review described in the ISPE Good Practice Guide: Technology Transfer.
1. Establish the Transfer Scope and Governance
Teams need to align on what is being transferred, the expected outcomes, and the activities used to confirm readiness. The transfer scope typically includes process descriptions, historical development data, analytical methods, batch records, and comparability considerations.
Governance is equally important. Tech transfer involves process development, analytics, quality, manufacturing, and program management. Effective governance supports clear role assignments, milestone tracking, and documented decisions. At Andelyn, this principle is reflected in the OneTeam™ approach to program management, which supports milestone transparency and decision clarity across functions.
2. Assess Process Knowledge and Manufacturing Readiness
Before execution, a practical assessment of process flow, unit operations, critical process parameters (CPPs), and critical quality attributes (CQAs) is necessary. In gene therapy, this stage is vital because scale-up can expose variability that is not evident at smaller scales. A readiness assessment helps identify where additional characterization or adaptation may be needed before moving into engineering or GMP runs.
3. Transfer and Confirm Analytical Methods
Analytical method transfer is foundational. It underpins product characterization, release readiness, and comparability. Without trust in the assays used to measure the product, manufacturing decisions cannot be made with confidence. This phase includes method documentation, training, assay establishment, and qualification or validation activities appropriate for the program's stage.
4. Execute Confirmation Activities at Scale
Small-scale studies, at-scale confirmation work, and engineering runs provide the opportunity to verify assumptions and evaluate process fit. These are not just procedural checkpoints; they generate data that informs the next stage of the journey. If outcomes differ from expectations, the data guides a disciplined investigation and potential process adjustments.
5. Maintain Transparency Through GMP Readiness
As a program reaches the GMP stage, tech transfer integrates with broader readiness, including quality systems and raw material strategy. This alignment supports a robust Pharmaceutical Quality System, as described in ICH Q10. By establishing clear management responsibilities and monitoring systems before engineering or GMP runs begin, sponsors and CDMOs can better support product realization and maintain control throughout the product lifecycle.
What to Look for in a CDMO Tech Transfer Partner
When evaluating a CDMO, the right partner should bring a disciplined execution framework. Consider these questions:
- Does the CDMO have experience with your specific modality and analytical methods?
- Can they support both process and analytical tech transfer?
- How is facility compatibility assessed during the transfer?
- What is the governance model for technical decisions and escalation?
- Is there a clear path from development through commercial manufacturing?
Conclusion: A Seamless Path to Scale-Up
Successful technology transfer is not just about moving data from one site to another; it is about building a foundation of knowledge and partnership that carries a therapy through clinical trials toward commercialization. By prioritizing transparency, cross-functional alignment, and rigorous risk assessments, sponsors can navigate the complexities of gene therapy manufacturing with confidence.
Partner with Andelyn Biosciences for Tech Transfer
Choosing the right CDMO partner is critical to ensure your process is scalable, stable, and ready for the clinic. At Andelyn, our approach combines deep technical expertise with a commitment to quality and transparency. Whether you are moving from bench to clinic or scaling up for commercial supply, we are here to support your mission of advancing therapies for patients in need.
Ready to discuss your tech transfer and manufacturing needs? Contact Andelyn Biosciences to connect with our team.
References
- World Health Organization. Annex 7: WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing. WHO Technical Report Series, No. 961, 2011.
- International Society for Pharmaceutical Engineering. Good Practice Guide: Technology Transfer, 2nd ed., 2014. ISPE Publication Record.
- International Council for Harmonisation. Guideline Q10: Pharmaceutical Quality System. Geneva, ICH Secretariat, 2008.
Introduction
Technology transfer is a critical step in the development of gene therapy. It is the point where process knowledge, analytical methods, documentation, and operational expectations must come together to support reliable execution at the next stage of manufacturing.
A successful technology transfer is not simply the movement of documents from one team or facility to another. It is a structured process of translating development knowledge into manufacturing execution. That includes assessing process fit, confirming analytical readiness, aligning responsibilities, and establishing the right level of control before engineering or GMP activities begin.
At its best, tech transfer creates a stronger foundation for scale-up by bringing together process development, analytical development, quality, manufacturing, supply chain, and program governance around a shared plan. The goal is not to remove complexity; it is to manage complexity responsibly, with decisions grounded in evidence, quality, and accountability.
What Tech Transfer Means in Gene Therapy Manufacturing
In gene therapy manufacturing, technology transfer is the structured transfer of process knowledge, analytical methods, materials information, documentation, and execution requirements. In practice, this often includes both process transfer and analytical method transfer. This approach aligns with the World Health Organization’s guidelines on transfer of technology in pharmaceutical manufacturing, which describe technology transfer as a planned and controlled process for moving product and process knowledge between development and manufacturing environments.
Process transfer focuses on how the product is made, including unit operations, raw material considerations, process parameters, scale-up strategy, and equipment compatibility. Analytical method transfer focuses on how the process and product are evaluated, including the assays, controls, and documentation required to establish methods in the receiving environment.
In gene therapy, this work is rarely straightforward. Programs often involve product-specific behavior, scale-dependent effects, and assays that continue to mature as development progresses. Regulatory expectations also become more demanding as programs advance. For those reasons, a strong CDMO tech transfer depends on more than technical capability alone: it requires coordination, transparency, and a shared commitment to doing the work the right way.
Why Tech Transfer Is a Defining Moment for Scale-Up
Scale-up is not only an operational milestone. It is a test of how well process knowledge can support reliable execution under new conditions.
A process that performs well in one setting may require further confirmation when transferred to a different team, facility, equipment train, or quality system. Even when core process elements remain the same, the context around them changes. Suite layout, operator practices, assay execution, and documentation workflows can all influence performance.
A well-planned tech transfer provides a structured approach to understanding this complexity, prioritizing risk, and supporting informed decisions before GMP execution begins. For programs advancing toward clinical manufacturing or commercial readiness, that structure supports better alignment across teams and a more reliable operational foundation.
The 5 Core Phases of a CDMO Tech Transfer Framework
The framework below reflects established technology transfer principles, including the importance of cross-functional planning, knowledge transfer, risk assessment, readiness activities, and documented review described in the ISPE Good Practice Guide: Technology Transfer.
1. Establish the Transfer Scope and Governance
Teams need to align on what is being transferred, the expected outcomes, and the activities used to confirm readiness. The transfer scope typically includes process descriptions, historical development data, analytical methods, batch records, and comparability considerations.
Governance is equally important. Tech transfer involves process development, analytics, quality, manufacturing, and program management. Effective governance supports clear role assignments, milestone tracking, and documented decisions. At Andelyn, this principle is reflected in the OneTeam™ approach to program management, which supports milestone transparency and decision clarity across functions.
2. Assess Process Knowledge and Manufacturing Readiness
Before execution, a practical assessment of process flow, unit operations, critical process parameters (CPPs), and critical quality attributes (CQAs) is necessary. In gene therapy, this stage is vital because scale-up can expose variability that is not evident at smaller scales. A readiness assessment helps identify where additional characterization or adaptation may be needed before moving into engineering or GMP runs.
3. Transfer and Confirm Analytical Methods
Analytical method transfer is foundational. It underpins product characterization, release readiness, and comparability. Without trust in the assays used to measure the product, manufacturing decisions cannot be made with confidence. This phase includes method documentation, training, assay establishment, and qualification or validation activities appropriate for the program's stage.
4. Execute Confirmation Activities at Scale
Small-scale studies, at-scale confirmation work, and engineering runs provide the opportunity to verify assumptions and evaluate process fit. These are not just procedural checkpoints; they generate data that informs the next stage of the journey. If outcomes differ from expectations, the data guides a disciplined investigation and potential process adjustments.
5. Maintain Transparency Through GMP Readiness
As a program reaches the GMP stage, tech transfer integrates with broader readiness, including quality systems and raw material strategy. This alignment supports a robust Pharmaceutical Quality System, as described in ICH Q10. By establishing clear management responsibilities and monitoring systems before engineering or GMP runs begin, sponsors and CDMOs can better support product realization and maintain control throughout the product lifecycle.
What to Look for in a CDMO Tech Transfer Partner
When evaluating a CDMO, the right partner should bring a disciplined execution framework. Consider these questions:
- Does the CDMO have experience with your specific modality and analytical methods?
- Can they support both process and analytical tech transfer?
- How is facility compatibility assessed during the transfer?
- What is the governance model for technical decisions and escalation?
- Is there a clear path from development through commercial manufacturing?
Conclusion: A Seamless Path to Scale-Up
Successful technology transfer is not just about moving data from one site to another; it is about building a foundation of knowledge and partnership that carries a therapy through clinical trials toward commercialization. By prioritizing transparency, cross-functional alignment, and rigorous risk assessments, sponsors can navigate the complexities of gene therapy manufacturing with confidence.
Partner with Andelyn Biosciences for Tech Transfer
Choosing the right CDMO partner is critical to ensure your process is scalable, stable, and ready for the clinic. At Andelyn, our approach combines deep technical expertise with a commitment to quality and transparency. Whether you are moving from bench to clinic or scaling up for commercial supply, we are here to support your mission of advancing therapies for patients in need.
Ready to discuss your tech transfer and manufacturing needs? Contact Andelyn Biosciences to connect with our team.
References
- World Health Organization. Annex 7: WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing. WHO Technical Report Series, No. 961, 2011.
- International Society for Pharmaceutical Engineering. Good Practice Guide: Technology Transfer, 2nd ed., 2014. ISPE Publication Record.
- International Council for Harmonisation. Guideline Q10: Pharmaceutical Quality System. Geneva, ICH Secretariat, 2008.
Introduction
Technology transfer is a critical step in the development of gene therapy. It is the point where process knowledge, analytical methods, documentation, and operational expectations must come together to support reliable execution at the next stage of manufacturing.
A successful technology transfer is not simply the movement of documents from one team or facility to another. It is a structured process of translating development knowledge into manufacturing execution. That includes assessing process fit, confirming analytical readiness, aligning responsibilities, and establishing the right level of control before engineering or GMP activities begin.
At its best, tech transfer creates a stronger foundation for scale-up by bringing together process development, analytical development, quality, manufacturing, supply chain, and program governance around a shared plan. The goal is not to remove complexity; it is to manage complexity responsibly, with decisions grounded in evidence, quality, and accountability.
What Tech Transfer Means in Gene Therapy Manufacturing
In gene therapy manufacturing, technology transfer is the structured transfer of process knowledge, analytical methods, materials information, documentation, and execution requirements. In practice, this often includes both process transfer and analytical method transfer. This approach aligns with the World Health Organization’s guidelines on transfer of technology in pharmaceutical manufacturing, which describe technology transfer as a planned and controlled process for moving product and process knowledge between development and manufacturing environments.
Process transfer focuses on how the product is made, including unit operations, raw material considerations, process parameters, scale-up strategy, and equipment compatibility. Analytical method transfer focuses on how the process and product are evaluated, including the assays, controls, and documentation required to establish methods in the receiving environment.
In gene therapy, this work is rarely straightforward. Programs often involve product-specific behavior, scale-dependent effects, and assays that continue to mature as development progresses. Regulatory expectations also become more demanding as programs advance. For those reasons, a strong CDMO tech transfer depends on more than technical capability alone: it requires coordination, transparency, and a shared commitment to doing the work the right way.
Why Tech Transfer Is a Defining Moment for Scale-Up
Scale-up is not only an operational milestone. It is a test of how well process knowledge can support reliable execution under new conditions.
A process that performs well in one setting may require further confirmation when transferred to a different team, facility, equipment train, or quality system. Even when core process elements remain the same, the context around them changes. Suite layout, operator practices, assay execution, and documentation workflows can all influence performance.
A well-planned tech transfer provides a structured approach to understanding this complexity, prioritizing risk, and supporting informed decisions before GMP execution begins. For programs advancing toward clinical manufacturing or commercial readiness, that structure supports better alignment across teams and a more reliable operational foundation.
The 5 Core Phases of a CDMO Tech Transfer Framework
The framework below reflects established technology transfer principles, including the importance of cross-functional planning, knowledge transfer, risk assessment, readiness activities, and documented review described in the ISPE Good Practice Guide: Technology Transfer.
1. Establish the Transfer Scope and Governance
Teams need to align on what is being transferred, the expected outcomes, and the activities used to confirm readiness. The transfer scope typically includes process descriptions, historical development data, analytical methods, batch records, and comparability considerations.
Governance is equally important. Tech transfer involves process development, analytics, quality, manufacturing, and program management. Effective governance supports clear role assignments, milestone tracking, and documented decisions. At Andelyn, this principle is reflected in the OneTeam™ approach to program management, which supports milestone transparency and decision clarity across functions.
2. Assess Process Knowledge and Manufacturing Readiness
Before execution, a practical assessment of process flow, unit operations, critical process parameters (CPPs), and critical quality attributes (CQAs) is necessary. In gene therapy, this stage is vital because scale-up can expose variability that is not evident at smaller scales. A readiness assessment helps identify where additional characterization or adaptation may be needed before moving into engineering or GMP runs.
3. Transfer and Confirm Analytical Methods
Analytical method transfer is foundational. It underpins product characterization, release readiness, and comparability. Without trust in the assays used to measure the product, manufacturing decisions cannot be made with confidence. This phase includes method documentation, training, assay establishment, and qualification or validation activities appropriate for the program's stage.
4. Execute Confirmation Activities at Scale
Small-scale studies, at-scale confirmation work, and engineering runs provide the opportunity to verify assumptions and evaluate process fit. These are not just procedural checkpoints; they generate data that informs the next stage of the journey. If outcomes differ from expectations, the data guides a disciplined investigation and potential process adjustments.
5. Maintain Transparency Through GMP Readiness
As a program reaches the GMP stage, tech transfer integrates with broader readiness, including quality systems and raw material strategy. This alignment supports a robust Pharmaceutical Quality System, as described in ICH Q10. By establishing clear management responsibilities and monitoring systems before engineering or GMP runs begin, sponsors and CDMOs can better support product realization and maintain control throughout the product lifecycle.
What to Look for in a CDMO Tech Transfer Partner
When evaluating a CDMO, the right partner should bring a disciplined execution framework. Consider these questions:
- Does the CDMO have experience with your specific modality and analytical methods?
- Can they support both process and analytical tech transfer?
- How is facility compatibility assessed during the transfer?
- What is the governance model for technical decisions and escalation?
- Is there a clear path from development through commercial manufacturing?
Conclusion: A Seamless Path to Scale-Up
Successful technology transfer is not just about moving data from one site to another; it is about building a foundation of knowledge and partnership that carries a therapy through clinical trials toward commercialization. By prioritizing transparency, cross-functional alignment, and rigorous risk assessments, sponsors can navigate the complexities of gene therapy manufacturing with confidence.
Partner with Andelyn Biosciences for Tech Transfer
Choosing the right CDMO partner is critical to ensure your process is scalable, stable, and ready for the clinic. At Andelyn, our approach combines deep technical expertise with a commitment to quality and transparency. Whether you are moving from bench to clinic or scaling up for commercial supply, we are here to support your mission of advancing therapies for patients in need.
Ready to discuss your tech transfer and manufacturing needs? Contact Andelyn Biosciences to connect with our team.
References
- World Health Organization. Annex 7: WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing. WHO Technical Report Series, No. 961, 2011.
- International Society for Pharmaceutical Engineering. Good Practice Guide: Technology Transfer, 2nd ed., 2014. ISPE Publication Record.
- International Council for Harmonisation. Guideline Q10: Pharmaceutical Quality System. Geneva, ICH Secretariat, 2008.